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Modern molecular high-throughput devices, e.g., next-generation sequencing, have
transformed medical research. Resulting data sets are usually high-dimensional on
a genomic-scale providing multi-factorial information from intertwined molecular and
cellular activities of genes and their products. This genomics-revolution installed precision
medicine offering breathtaking opportunities for patient’s diagnosis and treatment.
However, due to the speed of these developments the quality standards of the involved
data analyses are lacking behind, as exemplified by the infamous Duke Saga. In this
paper, we argue in favor of a two-stage cooperative serve model that couples data
generation and data analysis in the most beneficial way from the perspective of a patient
to ensure data analysis quality standards including reproducible research.
Keywords: computational biology, biostatistics, genomics, reproducible research, oncology, precision medicine,
data science

1. INTRODUCTION
Every new era provides opportunities but also challenges. For instance, at the early stage of
the Industrial Revolution several severe accidents happened, one of which was the explosion of
a steam boiler at a brewery in Mannheim in 1865. This and similar incidents resulted in the
establishment of the TÜV (english meaning is Technical Inspection Association) in Germany
as an independent institution for providing inspection and product certification services. Since
then from a high-tech nuclear power plant to a simple hair-dryer every factory, product or
service needs to pass a mandatory safety test from this independent association before it can be
put into operation. Different countries may have different implementation rules and enforcing
institutions but essentially every western country follows this model for all produces and services.
However, there is one notable exception to the above and this relates to the analysis services of
biomedical data.
An unfortunate example that demonstrates the catastrophic consequences of the lack of
quality control standards in data analysis services in genomic medicine is the Duke Saga (Kolata,
2011). Specifically, a re-analysis of cancer genomic studies conducted at the Duke University
by Anil Potti by external experts (Keith Baggerly and Kevin Coombes) from the MD Anderson
found that various publications contained fundamental flaws and even scientific misconduct
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This is also in contrast to most biostatistics and computational
biology departments at medical or clinical institutions, which
serve frequently merely as facilities to provide support for
other departments at the same institution. This implies
also that such facilities usually don’t have a budget for
developing new methods or for finding these, e.g., by a
comparative analysis.

(Baggerly and Coombes, 2009; Potti et al., 2011). These issues
were so severe leading ultimately in the discontinuation of
three clinical cancer trials that were started as a consequence
of Anil Potti’s research findings and the retraction of over ten
scientific papers, all published in renowned journals, including
the New England Journal of Medicine, Lancet Oncology and
Nature Medicine. Sadly, further examples along these lines are
ample (Ioannidis, 2005; Godlee et al., 2011; Simmons et al., 2011;
Gupta, 2013; Tripathi et al., 2013).

2.3. Similarities to the FDA
A related organization that has some similarities to our
envisioned external association is the Food and Drug
Administration (FDA) of the United States Department of
Health and Human Services. For instance, the FDA is involved
in the approval of medications, vaccinations and cosmetics.
However, in contrast to our model described above, the FDA
is predominantly concerned about outcome rather than the
process leading to an outcome. That means the FDA does
not perform experiments or computational analyses neither
does the FDA provide such services. Our external association
operates on a finer scale involved also in the process that leads to
the outcome.

2. MEASURES FOR ENSURING QUALITY
STANDARDS
In our opinion the Duke Saga has similarities to the steam
boiler explosion in Mannheim and we need to draw similar
consequences from this incident. Specifically, we suggest
that data analysis processes applied to medical, clinical and
biomedical data, from which conclusions are drawn that will
be used for the diagnosis or treatment of patients, need to be
approved and certified by an external association in order to
minimize the risk for patients. Here two important parameters
of such an external association are:
(A) The independence of the external association from the
data generating institution.
(B) The demonstrated expertise of the members constituting
the external association.

3. CONNECTION BETWEEN QUALITY
STANDARDS AND REPRODUCIBLE
RESEARCH
A problem that is tightly connected to ensuring quality standards
of data analysis results is reproducible research (Jasny et al.,
2011). In recent years, it has been recognized that in times of
increasing usage of advanced technologies for the generation of
data, requiring also more sophisticated data analysis methods,
ensuring the reproducibility of such studies is far from being
trivial. In fact, many studies have been identified that are lacking
this important requirement (Ioannidis et al., 2009; Nekrutenko
and Taylor, 2012). For this reason, minimal standards have been
established that should be followed (Sandve et al., 2013) and
important elements of such standards include:

2.1. Independence of the External
Association From the Data Generating
Institution
With respect to point (A), the independence of the external
association from the data supplying institution needs to include
its financial independence. This is in fact a problem with the
current system. Specifically, nearly every medical or clinical
institution maintains nowadays departments for biostatistics
or computational biology. However, the scientists employed
in these departments can hardly make decisions that are not
aligned to the strategic interests of the institution. In contrast,
an external association that is financially independent doesn’t
have to consider such strategic directions, in fact, it must not
consider these because flawed decisions can endanger the wellbeing of patients.

•
•
•
•

As a simple test for the reproducibility of a study it is often
informative to ask a colleague from a different department to
repeat the analysis, as described in the documentation. This
may reveal problems with different versions of software (e.g., R
packages), gaps in the documentation or inconsistencies in the
preprocessing of the data. Hence, even such a simple test can be
very helpful in spotting problems.
It is obvious that problems with the reproducibility of studies
could be easily avoided by the involvement of an external
association because general quality standards of a data analysis
include the requirement of its reproducibility. This underlines
that a wider look to a problem can be very beneficial because it
can lead to the resolution/avoidance of related problems.

2.2. Demonstrated Expertise of the
Members Constituting the External
Association
With respect to point (B), it is important that the members of
the external association have a PI status. This ensures the highest
possible standards of the quality control service that is needed
in a clinical context. This is necessary because the fast paced
developments in cancer genomics and its data analysis processes
require constantly novel solutions that are not available off-theshelf (Dunn and Bourne, 2017; Emmert-Streib and Dehmer,
2019).
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archive analysis software (including version control).
store seed of random number generator.
provide access to the analysis pipeline.
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4. PRACTICAL IMPLEMENTATION

A general characteristics of precision medicine and
personalized medicine is that advanced data generation
technologies are utilized in combination with sophisticated data
analysis methods (Auffray et al., 2009; Ginsburg and Willard,
2009; Emmert-Streib and Dehmer, 2018). Since this is very
similar to cancer genomics a corresponding translation of our
outlined model should be transferable to other disease domains
of precision medicine, e.g., immunology, neurodegenerative
diseases or diabetes.
A current example that adds to our argument is given by
Zolgensma. Zolgensma is an FDA approved gene therapy by
Novartis intended to treat children with spinal muscular atrophy
(SMA). This is the most severe form of SMA. On June 28 2019 the
FDA was informed by AveXis about a data manipulation issue
during product testing (FDA, 2019; Tirrell, 2019). This is also
an example demonstrating the severity of the problem beyond
oncology raised in this paper that can effect the life of patients
and even children. Another example is the ban of the European
Union of around 700 generic medicines for alleged manipulation
of clinical trials conducted by the company GVK Biosciences
(EMA, 2015).

So far we discussed the problem from a principle point of view.
Now we turn to the practical implementation. In Figure 1, we
summarize our discussion by providing a graphical visualization
of the interplay between a data generating institution (outlined
in blue) and an external association (outlined in orange). Here
we distinguished visually between two components that are
both part of the external association. The first involves all
practical aspects of the data analysis including preprocessing
and data integration, whereas the second one is only concerned
with conclusions and recommendations derived from such
an analysis.
Given the fact that many data generating institutions have
already facilities for the analysis of data, e.g., biostatistics units,
it would be efficient to utilize these in the following way. Instead
of leaving it to the facilities to decide how to analyze the data, the
external association should establish certified analysis protocols
to follow. That means instead of performing the data analysis
externally, it could be performed internally by the data generating
institution itself, however, by following strict guidelines. In
this way the lack of a research budget of facilities to establish
optimal analysis protocols is compensated by the expertise of the
external association.
As a side-effect, this would also deal with the problem of
reproducibility because this is part of overall sound quality
standards. Hence, only the part of the data analysis concerned
with conclusions and recommendations should be under the sole
governance of the external association.

7. DISCUSSION
Due to the difficulty of the raised problem, we would like to
clarify some further issues. First, our arguments are limited
to biomedical studies involving either directly or indirectly
patients. However, our arguments do not extend to general
biological studies. The reason for this is that here we are not
concerned with general reproducibility problems of studies but
with consequences of such issues for patient treatment and care.
That means, in our opinion, we focus on the most severe problem
we are currently facing. If our arguments should also be extended
to biological studies is open for discussion.
The crucial point is whether the outcome of an analysis
from either diagnostic, prognostic or predictive investigations is
affecting the treatment of patients with a clear causal connection
between both. That means the analysis needs to inform the
treatment. Hence, for instance an analysis of patient-derived
cell lines, which only indirectly involves patients, falls under
this category if the outcome of this analysis has a direct
influence on the patient’s treatment. It is clear that much of
biomedical research is not directly concluding on any issue
related to patient treatment, but instead typically investigates
biological mechanisms.
Second, it is clear that the translation of biological findings
toward their clinical usability is a long and difficult endeavor.
As an example, we would like to mention the known difficulties
of finding reproducible prognostic methylation biomarkers
for colorectal cancer (Draht et al., 2018) or general cancers
(Koch et al., 2018). This just underlines the difficulties we are
facing experimentally and computationally requiring stringent
protocols to safeguard against spurious results.
Third, in order to make an impact, we belief it is necessary
to specify our scope precisely. The problem is that precision
medicine or personalized medicine could refer to highly variable

5. HIGHER STANDARDS BY A
COOPERATION SERVICE MODEL
We would like to emphasize that we consider the interplay
between a data generating institution and an external association
as a cooperation. The reason is that in research areas involving
patients, the well-being and interests of the patients are top
priority. This implies that it is not possible to keep analysis
protocols shut way. In turn this means it will always be possible
to reveal potential shortcomings or errors, as accomplished by
Baggerly and Coombes (2009) and (Potti et al., 2011), because
if undiscovered such errors will otherwise lead to physical or
psychological harm of patients. Hence, in order to achieve the
best possible outcome for the patients a cooperation between all
involved parties is required that share responsibilities.

6. QUALITY STANDARDS AND
REPRODUCIBLE RESEARCH BEYOND
ONCOLOGY
The above discussion centered around cancer genomics data
and the Duke Saga which happened in oncology (involving
breast, colon, ovarian and lung cancer). However, we are of
the opinion that such a collaborative model between a data
generating institution and an external association as outlined
above should be also beneficial for fields other than oncology.
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FIGURE 1 | Visualization of the interplay between a data generating institution, e.g., a hospital or a medical institution, and an external association. Overall, this
represents a two-stage cooperative service model.

in Bozzo et al. (2017) the authors identified 571 retracted
publications in the cancer research literature of which 28.4%
of the retrations were due to fraud and 24.2% due to errors.
Further examples are provided in George and Buyse (2015) where
the fabrication or falsification of data in clinical trials has been
investigated effecting hundreds of publications in the literature.

settings, ranging from basic research employing patient samples
to decipher disease biology to drug development or clinical
assessment. Unfortunately, these examples show that defining
a scope precisely is not straight forward since all of these
sub-studies relate to “patients”. For this reason, we suggest an
assessment of the outcome of a study if it can potentially “harm a
patient.” In this way the problem is converted to a legal issue and
its definition is given by country-specific laws.
Fourth, data privacy is a current issue of great relevance in the
big biomedical data era (Malin et al., 2013; Patil and Seshadri,
2014). However, our focus is on preventing patient harm due to
inadequate data analysis standards. Of course, patients could also
suffer from data privacy violations by third parties, however, not
due to inadequate data analysis standards. Hence, data privacy
is an issue data analysis services need to adhere to but for
different reasons.
Fifth, erroneous data analysis results could come from
deliberate cheating or other forms of scientific flaws.
Interestingly, from a patient perspective, the potential harm is
the same. However, safeguarding against the former threat is
naturally accomplished by an external association because many
of the incentives are eliminated in this way.
Sixth, problems of the sort discussed in this paper are actually
rather widespread. For instance, in a survey study conducted
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8. CONCLUSIONS
A necessary step toward the practical realization for the
certification of medical and clinical data analysis services would
require the authorities to become active. For instance, legal laws
could be legislated making the acquisition of such certificates
mandatory attesting the fulfillment of quality standards. In turn,
this would enable the establishment of external associations,
similar to the model of the TÜV. If the Duke Saga could have been
prevented is speculation. However, given the fact that Baggerly
and Coombes (2009) were capable of reverse engineering some
errors it appears reasonable to assume that an external association
could have picked up these at an early stage before entering
clinical trials.
In MacArthur (2012) it is argued that “Flawed papers cause
harm beyond their authors: they trigger futile projects, stalling
the careers of graduate students and postdocs, and they degrade
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FUNDING

the reputation of genomic research.” Importantly, we would
like to add that flawed medical data analysis services can even
severely harm the life of patients. In summary, we argued
in favor of a “trust, but verify” approach because since the
Duke Saga no legislative changes were initiated allowing history
to repeat.
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